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Abstract
Testosterone replacement therapy (TRT) has been shown to improve the symptoms of metabolic
syndrome by reducing Hemoglobin A1C, belly fat, cholesterol, and blood pressure
(Cunningham, 2015). The ultimate goal for testosterone-deficient patients is to have an improved
quality of life by starting TRT. This quality improvement project was conducted at a small,
primary care clinic in South Texas. The project was started by screening 84 male patients equal
to or over 40 years of age using the Androgen Deficiency in Aging Males (ADAM)
questionnaire. The ADAM questionnaire was considered positive for anyone who answered
“yes” to 3 or more questions or “yes” to questions 1 or 7 (Morley et al., 2000). Out of the 84
patients screened by the ADAM questionnaire, 57 screened positive for low testosterone. Only
23 of those 57 patients agreed a confirmatory testosterone blood test; 20 of those 23 had low
testosterone blood levels. Any patient who had an abnormally low testosterone level was given
the option to start TRT. Eleven of the 20 patients included in the project accepted TRT. After 6
to 8 weeks of testosterone replacement therapy, patients were given the ADAM questionnaire
again to assess if improved scores had occurred. After starting TRT, only 1 of the 11 participants
had an unchanged ADAM score although it was noted his testosterone levels were still
subtherapeutic. Ten of the 11 participants who received TRT had improved ADAM scores at the
end of the project window. The ADAM questionnaire has a sensitivity of 88%-97%, so poor
ADAM scores were highly linked to low total testosterone levels (Lunenfeld et al., 2015; Morley
et al., 2000).
Keywords: low testosterone, metabolic syndrome, depression, erectile dysfunction, low
sex drive, lack of energy, muscle loss, androgen deficiency; aging males
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Baby boomers are getting older and the life expectancy of humans is increasing. This
translates to primary care providers caring for more geriatric patients than their predecessors.
The increased geriatric patient load leads to an increase in comorbidities that often accompany
the aging population. One of those comorbidities in men is low testosterone. Although many men
experience the signs of low testosterone, most assume it is a normal part of aging that does not
need to be treated (Mayor, 2016). They are also misinformed on testosterone replacement
therapy (TRT) (Mayor, 2016). Some providers also have misconceptions of low testosterone and
TRT, so they refuse to prescribe it to their patients (Mayor, 2016).
Patients and providers must to be educated on the effects of low testosterone and its
effect on the quality of life in aging males. Some of these effects include increased risk of
cardiovascular disease, diabetes, depression, osteoporosis, fatigue, erectile dysfunction,
decreased sex drive, loss of muscle mass, and fat gain (Cunningham, 2015; Snyder et al., 2016;
Sugerman, 2013). Patients should be provided with the benefits and drawbacks of TRT in order
to consider incorporating as part of their regular medication regimen. Identification of
subtherapeutic testosterone levels can be facilitated by administration of the Androgen
Deficiency in Aging Males (ADAM) questionnaire during routine primary care visits.
Statement of the Problem
Testosterone levels in men have been decreasing from generation to generation. The
normal testosterone range in healthy men is between 300 and 1000 ng/dL; it peaks in the late
20s, but it begins to decline by 1.5% to 2% in the early 30s (Hellstrom, 2013; Travison, Araujo,
O’Donnell, Kupelian, & McKinlay 2007). According to Travison et al. (2007), men have been
losing testosterone, but it is not just age-related. In the same study, men aged 65 to 69 years had
higher testosterone levels in 1988 (503 ng/dL) than men in the same age group in 2003 (423
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ng/dL) (Travison et al., 2007). On a positive note, these men can be treated with TRT to increase
their testosterone levels to a normal range.
Background and Significance
Low testosterone levels have been linked to decreased sexual function and depression
(Mayo Clinic, 2019; Snyder et al., 2016). This means some men are being misdiagnosed as
having depression when the etiology is low testosterone. The diagnostic criteria for depression is
met but the source of the depression is improperly treated. Chronic problems such as diabetes
and hyperlipidemia are also worsened by low testosterone levels (Sugerman, 2013). Men with
low testosterone are also more likely to develop osteoporosis, muscle weakness, and decreased
energy levels (Sugerman, 2013). This constellation of symptoms means men with a lower
testosterone levels may have a lower quality of life.
TRT can reverse most of these problems. Unfortunately, it comes with some
misconceptions. One myth regarding TRT is it causes an increased risk of prostate cancer.
Lunenfeld et al. (2015) looked at over 3,000 patients with 6,000 controls and found no
correlation between serum testosterone levels and prostate cancer. There was also no significant
correlation between TRT and prostate cancer (Lunenfeld et al., 2015). In another study, Snyder
et al. (2016) did note that one out of 394 patients on TRT was diagnosed with prostate cancer.
Assessment
The family practice clinical partner for this quality improvement project was located in
northeast San Antonio. The clinic’s patient profile comprised 50% Hispanic, 30% White, 10%
Black, and 10% Other. Many of the patients often present to the clinic for depression,
hyperlipidemia, hypertension, hyperglycemia, and decreased energy levels. Of the100 random
charts of men equal to or older than 40 years of age reviewed, 65 had hypertension, 91 had
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hyperlipidemia, 59 had hyperglycemia and 42 had all three diagnosis. These men who visit this
clinic could have a low testosterone level manifesting as the aforementioned diagnoses. The
clinic did not have an assessment tool or protocol in place to query men equal to or over 40 years
about symptoms traditionally associated with low testosterone.
Organization’s Readiness for Change
The results of the microsystem assessment done in May 2018 were presented to the staff
of the clinic to ensure understanding of the need for a testosterone screening tool. The ADAM
questionnaire has a sensitivity of 88% to 97% (Lunenfeld et al., 2015; Morley et al., 2000). After
presenting the results of the microsystem analysis to the staff, they agreed the ADAM
questionnaire should be used to try to better identify patients with low testosterone.
Project Identification
Purpose
The purpose of this quality improvement project was to use the ADAM questionnaire as a
screening tool to identify men equal to or over 40 years of age with low testosterone levels and
recommend TRT when not contraindicated by personal choice or a comorbid medical condition.
Objectives
The objectives of the quality improvement project were:
1. Use the ADAM questionnaire to increase the screening of males equal to or over
40 years for low testosterone who presented to the clinic from 0% to 75%.
2. Order serum total testosterone levels on 90% of the patients identified by the
ADAM questionnaire as potentially having low testosterone.
3. Offer TRT to 90% of patients who have confirmed low serum total testosterone
levels.
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4. Have patients started on TRT return for follow-up visit after one month to readminister the ADAM questionnaire.
5. Improve the quality of life in males with hypoandrogenism through TRT as
evidenced by an improved score in the parameters outlined in the ADAM
questionnaire.
Anticipated Outcomes
By meeting the objectives of the project, the outcome was an increased identification,
treatment, and management in the participants with hypoandrogenism. This may also lead to
reduced Hemoglobin A1C, belly fat, cholesterol, and blood pressure among other comorbidities;
however, these associated parameters were not included in the scope of this study (Cunningham,
2015). The clinic will now be able to treat patients with low testosterone according to the
American Urology Association guidelines.
Summary and Strength of the Evidence
The ADAM questionnaire is a tool utilized to help identify males with low testosterone;
in one study it demonstrated 88% sensitivity and 60% specificity (Morley et al., 2000). In
another study, the sensitivity was 97% but the specificity was only 30% (Lunenfeld et al., 2015).
The high sensitivity of these studies suggests the ADAM questionnaire may help identify males
with low testosterone. Nevertheless, the low specificity makes it hard to identify those with
normal total testosterone levels. Since it is not specific enough to stand alone, a blood test will be
the definitive diagnostic tool used to diagnose low testosterone (Cabral, Busin, Rosito, & Koff,
2014).
There are many reasons men choose to start TRT. What can be certain is most do not
know the dangers low testosterone levels have on their health. In fact, men are at higher risk for
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stroke, myocardial infarction, and sudden death when they have low testosterone levels
(American Urology Association, 2018). TRT has been shown to improve weight loss, libido,
depression, and fatigue in men who have HIV (Hellstrom, 2013). It is plausible to reproduce
similar results in men without HIV. According to Snyder et al. (2016), men treated with TRT had
an increase in sexual desire, sexual function, erectile function and mood on the Psychosexual
Daily Questionnaire. In fact, one study compared testosterone levels of 120 males and found
patients with diabetes type 2 had a total testosterone level almost 100 ng/dL lower than patients
without diabetes type 2 (Bansal, Kumar, Pathak, & Manglunia, 2017). One asks the question,
“Which came first?”
Some side effects of TRT are still undetermined but there is evidence that TRT may lead
to increased hemoglobin, hematocrit and prostate specific antigen (PSA) (American Urology
Association, 2018). According to Lunenfeld et al. (2015), the PSA may increase over the first
few months of TRT so the new baseline should be taken 6 months after TRT was started. Even
with the increased PSA levels, there was no evidence of increased risk for prostate cancer
(Lunenfeld et al., 2015). Several factors can affect the PSA; a urinary tract infection or prostatitis
can increase it while medications used for benign prostatic hypertrophy can decrease it (National
Cancer Institute, 2017). An article in The New England Journal of Medicine suggests periodic
monitoring of prostate and cardiovascular health for men receiving TRT to ensure they do not
experience any adverse effects (Swerdloff & Anawalt, 2014).
Many cardiologists are fearful about starting TRT on patients because they have read
reports that TRT can have adverse cardiac effects, but the FDA has found many flaws in these
reports (Cunningham, 2015). In fact, Cole et al. (2018) conducted a study with over 3,400 men
aged 40 to 64 years on TRT who were either military spouses, retired military, or current military
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and found they actually had a lower risk of coronary artery disease (CAD) compared to the
control group p = 0.008. An article from the Journal of the American College of Cardiology
examined 59 randomized control trials involving over 4,000 patients assigned to a testosterone
group and over 3,000 assigned to a placebo group and found no significant difference in death
from major adverse cardiovascular events including myocardial infarction or stroke (Kip et al.,
2019).
Providers need to have sufficient knowledge about TRT to ensure patient safety.
Lunenfeld et al. (2015) suggests using a TRT that is shorter acting in case it needs to be stopped
due to side effects or adverse effects. TRT should not be started if hematocrit baseline is higher
than 50% because it has been shown to increase the hematocrit (Lunenfeld et al., 2015). The risk
for obstructive sleep apnea (OSA) was increased with the TRT group when compared to the
control group (Cole et al., 2018). Therefore, providers should screen their patients for sleep
apnea prior to starting any TRT. The patient and provider need to discuss the risks and benefits
of TRT to ensure positive therapeutic outcomes. Until further research is conducted to identify
the potential side effects of TRT, the ultimate decision falls on the patient.
Methods
Project Intervention
The project was conducted on male patients at least 40 years of age. Age-eligible patients
presenting to a northeast San Antonio family practice clinic were administered the ADAM
questionnaire in English. Once the ADAM questionnaire was completed, the provider offered
further education on acquired hypoandrogenism if the patient answered “yes” to three or more
questions or if he answered “yes” to question 1 or 7 (Morley et al., 2000). Every patient who
screened positive on the ADAM questionnaire was offered an opportunity to have his total
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testosterone blood levels drawn to confirm the diagnosis of hypoandrogenism. The patients had
to have their testosterone levels drawn on two separate days in the morning when levels peaked
(Sugerman, 2013). Patients also had their PSA and Hematocrit drawn before beginning TRT
regimen (American Urology Association, 2018). Patients with a low total testosterone blood
level below 300 ng/dl were offered TRT (American Urology Association, 2018). They were
started on 1 mL of Testosterone Cypionate 200mg/mL Intramuscularly (IM) every two weeks in
an effort to increase their total testosterone levels to 450-600 ng/dL (American Urology
Association, 2018). After 6 to 8 weeks of TRT, the patients returned to the clinic to check their
total testosterone levels. The TRT dosage was titrated base on the total testosterone results. They
were also given the ADAM questionnaire to reassess symptoms. Both sets of ADAM
questionnaire results were compared to identify changes associated with the administration of
TRT.
Organizational Barriers, Facilitators, and Ethical Concerns
Patient records were kept at the clinic in a locked cabinet to comply with the Health
Information Portability and Accountability Act. The family practice clinic partner associated
with this project has previously implemented Doctor of Nursing Practice projects with great
success. To ensure the regulatory and ethical compliance of this quality improvement project, the
University of the Incarnate Word Institutional Review Board was consulted. The Institutional
Review Board determined this project did not meet federal monitoring requirements for research
involving human subjects, NRR# 18-026.
Results
The ADAM questionnaire was given to a total of 84, age-eligible males who came to the
clinic in a four-week period in February and March of 2019 (Objective #1 met). The mean age of
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the participants was 53 years. Of the 84 patients screened with the ADAM questionnaire, 57
screened positive for hypoandrogenism. All 57 patients who screened positive on the ADAM
questionnaire were offered a total testosterone blood test to confirm the suspected diagnosis.
Only 23 of those 57 patients agreed to the total testosterone blood test. Twenty of the 23
participants did have low serum testosterone levels. Objective #2 was not met as only 40% of the
patients who screened positive for low testosterone agreed to have a total testosterone blood level
drawn. All 20 of the patients who had a low total testosterone blood level were offered TRT, but
only 11 out of the 20 decided to start TRT. Objective number three was not met because only
55% of the patients with a low total testosterone blood level agreed to begin TRT. The electronic
medical records of all 11 patients were evaluated for metabolic syndrome, the results are shown
in Figure 1.
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Figure 1. Comorbidities of the TRT group. The figure shows the percentage of each comorbidity
found in participants during the screening for metabolic syndrome.
At four to six weeks after initiating TRT, 10 of the 11 patients returned to the clinic to
have their testosterone levels drawn again (Objective #4 met). All 10 were also re-administered
the ADAM questionnaire. After starting TRT, only one of the 10 participants continued with
subtherapeutic serum total testosterone levels (<300 ng/dL). He also did not have any changes on
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the ADAM scores. The other nine patients who were at a therapeutic testosterone level had
significant improvements on the ADAM questionnaire (Objective #5 met). The differences in the
ADAM scores before and after TRT can be found on Figure 2.
Before TRT
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Figure 2. ADAM results before and after TRT. Percentage of patients who answered yes on the
ADAM questionnaire before and after starting TRT.
Discussion
Some of the objectives were not met because many patients did not want to participate
beyond filling out the ADAM questionnaire. The time limit of the project made it difficult to
monitor for changes in comorbidities such as hypertension, hyperlipidemia, diabetes, and
obesity. Every patient who reached therapeutic levels of testosterone had improved ADAM
scores. The ADAM questionnaire proved to be a reliable tool. The sensitivity of the tool in this
project was measured at 87%, close to the 88% sensitivity documented in the literature (Morley
et al., 2000).
Limitations
The project had a very low sample size due to the lack of patient participation. Some men
(34 out of 57) were not willing to have their blood levels drawn to see if they had low
testosterone. Another challenge was 11 out of the 20 who had low testosterone levels did not
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agree to start TRT. According to the research the specificity is too low to allow the ADAM
questionnaire to be a stand-alone tool to diagnose low testosterone (Ugwu & Ikem, 2017). That
means providers need to do a blood draw to formally diagnose patients with low testosterone.
This is a problem for those patients do not have time to return to the clinic for serial blood draws.
Recommendations
The ADAM questionnaire is a good screening tool that can be incorporated in primary
care settings to screen men  40 years of age for acquired hypoandrogenism. This tool will help
identify men with low testosterone who are oblivious about their condition. This project also
exposed the need to educate patients on the benefits and drawbacks of TRT as well as the risks of
sustained low serum testosterone levels. The ADAM questionnaire is also available in many
languages and it is free to use. According to the American Urology Association (2018), men
should be started on testosterone if they are below 300 ng/dL and they should be brought to a
therapeutic level of between 450-600 ng/dL. This suggests the American Urology Association
recommends a testosterone level of at least 450 ng/dL so men who are between 300-450 ng/dL
may also benefit from TRT.
Implications for Practice
The Doctor of Nursing Practice essentials were used to determine the implications for practice.
1. Scientific Underpinnings for Practice


A literature review was done to identify comorbidities of low testosterone.

2. Organizational and Systems Leadership for Quality Improvement and Systems Thinking


A systematic review of 100 electronic medical records was conducted to identify
patients with the comorbidities associated with low testosterone.

3. Clinical Scholarship and Analytical Methods for Evidence-Based Practice
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Evaluated clinical site’s use of any tools to identify low testosterone.

4. Information Systems / Technology and Patient Care Technology for the Improvement
and Transformation of Health Care


Utilized the electronic medical records at the clinic to track all lab results on
patients screened for low testosterone.

5. Health Care Policy for Advocacy in Health Care


Implemented the use of the ADAM questionnaire to help identify men  40 with
low testosterone so they could be treated with TRT.

6. Inter-Professional Collaboration for Improving Patient and Population Health Outcomes


Met with all staff involved in the project to explain each individual’s essential
role in the project and remained available for any questions or input the staff had
during the project.

7. Clinical Prevention and Population Health for Improving the Nation’s Health


The project was available to all male patients 40 or older who came to the clinic.
All patients who screened positive for low testosterone were offered the total
testosterone blood test and anyone identified with low testosterone was offered
TRT.

8. Advanced Nursing Practice


Mentored staff on the direction of the project to ensure the project was completed
to the best of their abilities.
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Appendix
Androgen Deficiency in Aging Males (ADAM) questionnaire
Name: __________________________________________________
Date of birth: ___________________________________________________
Today’s date: __________________
ADAM questionnaire includes ten questions please circle: Yes or No
1. Do you have a decrease in libido (sex drive)? Yes No
2. Do you have a lack of energy? Yes No
3. Do you have a decrease in strength and/or endurance? Yes No
4. Have you lost height? Yes No
5. Have you noticed a decreased ‘enjoyment of life’? Yes No
6. Are you sad and/or grumpy? Yes No
7. Are your erections less strong? Yes No
8. Have you noted a recent deterioration in your ability to play sports? Yes No
9. Are you falling asleep after dinner? Yes No
10. Has there been a recent deterioration in your work performance? Yes No
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